Non-Hodgkin's Lymphoma Clinical Trials

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Phase: 2

Protocol Number: 15-547

A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).

Diagnosis: Non-Hodgkin's Lymphoma

Phase: 2

Protocol Number: 16-118

Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Diagnosis: Solid Tumor/Phase I, Non-Hodgkin's Lymphoma

Phase: 1 / 2

Protocol Number: 15-207

A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in...

Diagnosis: Non-Hodgkin's Lymphoma

Phase: 1 / 2

Protocol Number: 15-238

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds t...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 17-075

Axicabtagene Ciloleucel Expanded Access Study

This is a multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory transplant ineligible aggressive NHL.

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 17-125

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

This study will explore whether ivabradine lowers heart rate, and thus improves exercise capacity, in survivors of lymphoma who have an elevated resting heart rate as a side effect of prior radiati...

Diagnosis: Pediatric Non-Hodgkin Lymphoma, Pediatric Hodgkin Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 17-022

Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of imp...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 17-720

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 18-322

Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia and Margi...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 18-353

Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

To evaluate the safety and tolerability, find an appropriate dose to optimize safety and efficacy, and evaluate clinical activity of PBCAR0191 in subjects with relapsed/refractory (r/r) B-cell acut...

Diagnosis: Non-Hodgkin's Lymphoma, Leukemia/MDS

Phase:

Protocol Number: 18-608

DS-3201b in Participants With Lymphomas

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research. Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their dise...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 19-063